Handbook of chronic myeloid leukemia: [electronic resource] /: Timothy P Hughes, David M Ross, Junia V Melo.

Hughes, Timothy P.,; Ross, David M.,; Melo, J. V.

doi:10.1007/978-3-319-08350-6

Handbook of chronic myeloid leukemia [electronic resource] / Timothy P Hughes, David M Ross, Junia V Melo.

Hughes, Timothy P., author.; Ross, David M., author.; Melo, J. V. (Junia V.), author.

2014

RC643

Available Online

Formats

Format
BibTeX
MARCXML
TextMARC
MARC
DublinCore
EndNote
NLM
RefWorks
RIS

Add to Basket

Cite

Linked e-resources

Linked Resource

Online Access

Details

Title

Handbook of chronic myeloid leukemia [electronic resource] / Timothy P Hughes, David M Ross, Junia V Melo.

Author

Hughes, Timothy P., author.

ISBN

9783319083506 electronic book
3319083503 electronic book
9783319083490
331908349X

DOI

https://doi.org/10.1007/978-3-319-08350-6

Published

Cham : Adis, 2014.

Language

English

Description

1 online resource (xiii, 65 pages) : illustrations (some color)

Item Number

10.1007/978-3-319-08350-6 doi

Call Number

RC643

Dewey Decimal Classification

616.99/419

Summary

This concise, clinically focused pocket handbook assembles and synthesizes the latest developments and trends in the diagnosis and treatment of CML and provides an authoritative and convenient summary of the latest progress in TKI trials, the molecular monitoring of CML responses, and the development of new therapies to overcome resistance and improve patient care. Chronic myeloid leukemia (CML) is a rare type of leukemia (1?2 per 100,000 people) but is the most common chronic myeloproliferative neoplasm. CML remains a key model for the improved understanding of the pathophysiology of a malignancy at a molecular level; CML was the first cancer to be associated with a recurring chromosome abnormality, which generates the Philadelphia (Ph) chromosome and its associated fusion gene BCR-ABL1. The clinical outcome for patients with CML has changed dramatically in the past 15 years and this has been due to the development of tyrosine kinase inhibitors (TKIs), compounds that inhibit the activity of the oncogenic BCR-ABL1 protein. A number of first-, second- and third-generation TKIs are now available for the treatment of CML, although a number of treatment challenges remain, not least the development of treatment-resistant CML. Parallel to the development of specific drugs for treating CML, major advances have been made in the field of disease monitoring and standardization of response criteria.

Bibliography, etc. Note

Includes bibliographical references.

Access Note

Access limited to authorized users.

Source of Description

Online resource; title from PDF title page (SpringerLink, viewed December 3, 2014).

Added Author

Ross, David M., author.
Melo, J. V. (Junia V.), author.

Available in Other Form

Print version: 9783319083490

Linked Resources

Online Access